m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02771)
Name
PMID17935984C1
Synonyms
CHEBI:45030; 1you; AC1LCVYP; GTPL6526; BDBM50224854; DB08388
    Click to Show/Hide
Status
Clinical trial
Structure
Formula
C20H19FN2O6
InChI
1S/C20H19FN2O6/c1-2-27-12-11-20(17(24)22-19(26)23-18(20)25)29-16-9-7-15(8-10-16)28-14-5-3-13(21)4-6-14/h3-10H,2,11-12H2,1H3,(H2,22,23,24,25,26)
InChIKey
XRSYNYGEEYTXJV-UHFFFAOYSA-N
PubChem CID
657061
TTD Drug ID
D0A4RF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-13 (MMP-13)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for PMID17935984C1. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PMID17935984C1 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for PMID17935984C1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMID17935984C1 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [2], [3]
References
Ref 1 FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020 Apr 1;389(1):111894. doi: 10.1016/j.yexcr.2020.111894. Epub 2020 Feb 6.
Ref 2 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. doi: 10.1016/j.bmcl.2005.12.020. Epub 2006 Jan 19.
Ref 3 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.